Ribbon cutting of the new facility (left to right): Dr. Hari Nair, Executive Chairman, PrIME Biologics, Mr. Kevin Lai, Executive Director, Biomedical Sciences and Consumer Businesses, Singapore Economic Development Board.
PrIME Biologics Opens Plasma Fractionation Facility08 October 2014
On 8 October, Singapore-based biotech firm PrIME Biologics inaugurated its new plasma fractionation facility in Singapore, which is the first of its kind in South-east Asia. The high-tech new plant is installed in its certified facility at Science Park II, where it will manufacture emergency drugs by using a new and innovative patented technology that was pioneered by the company. This technology is touted to be "smaller, safer, faster and cheaper" compared to the conventional way of processing plasma, due to a special membrane used by PrIME. The new plant can process 20,000 to 30,000 litres of plasma per year.
The technology is especially relevant to the Asian market. Due to the lack of sophisticated blood banks in countries like India and Vietnam, the collection of human blood plasma is difficult and these countries dispose plasma as they are unable to process it effectively. PrIME technology takes 'currently unprocessable plasma' (CUP) and separates proteins from CUP and normal plasma. Eventually, this novel technology ensures that Asian countries are self-sufficient - a goal that the World Health Organisation is strongly pursuing.
Blood plasma products are a US$11.8 billion global market, of which an estimated US$1.8 billion is in Asia. The market is currently dominated by four manufacturers - Baxter, CSL, Grifols and Octapharma. This facility is expected to be registered with the Health Sciences Authority by the end of the year. Once the PrIME facility is up and running, the firm is looking to duplicate it in India, South-east Asia, the Middle East and Africa, respectively.
08 October 2014
Press Release and Speech